Novo Nordisk has piled yet another obesity program on its plate. Seeking to build on its early lead in the blockbuster market, the Danish drugmaker has agreed (PDF) to pay EraCal Therapeutics up to 235 million euros ($255 million) to work on a novel mechanism of action for controlling appetite and body weight.EraCal, a Swiss […]
